© 2022 MJH Life Sciences and Ophthalmology Times. All rights reserved.
© 2022 MJH Life Sciences™ and Ophthalmology Times. All rights reserved.
June 23, 2021
Increased access is key to preventing disease progression in patients.
June 15, 2021
Physicians are left to determine which treatments can offer patients best outcomes.
June 14, 2021
Retrospective review highlights the sustained efficacy of combination procedure.
June 11, 2021
RGX-314 eyed by investigators as a therapeutic option for exudative AMD.
June 09, 2021
Bi-sign design compensates for aberrations resulting from misalignment.
June 07, 2021
Use of such procedures increased markedly in analysis of IRIS Registry Data.
June 04, 2021
UK physician notes a full systemic work-up needed to determine source of infection.
June 03, 2021
Study results show that aflibercept-treated eyes are protected.
June 02, 2021
Study results show the device offers an effective long-term option for patients.
June 01, 2021
Therapeutic choices beneficial for patients may be available in 1 to 3 years.
May 31, 2021
A word from Chief Medical Editor Peter J. McDonnell, MD.
May 07, 2021
Check out the latest cartoon!
May 05, 2021
Short learning curve, significant clinical advantages make this a comfortable addition.
April 29, 2021
Clues to dangerous etiologies include pain and positive imaging findings.
Stealth BioTherapeutics announces data from Phase 2 study of geographic atrophy candidate
Ocuphire announces positive topline results from LYNX-1 Phase 3 trial
Kala reaches deal to sell Eysuvis, Inveltys to Alcon